AU2016282782A1 - Methods of treating autoimmune and alloimmune disorders - Google Patents

Methods of treating autoimmune and alloimmune disorders Download PDF

Info

Publication number
AU2016282782A1
AU2016282782A1 AU2016282782A AU2016282782A AU2016282782A1 AU 2016282782 A1 AU2016282782 A1 AU 2016282782A1 AU 2016282782 A AU2016282782 A AU 2016282782A AU 2016282782 A AU2016282782 A AU 2016282782A AU 2016282782 A1 AU2016282782 A1 AU 2016282782A1
Authority
AU
Australia
Prior art keywords
ser
gly
thr
tyr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016282782A
Other languages
English (en)
Inventor
Pavel A. NIKITIN
Sandip PANICKER
Graham Parry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioverativ USA Inc
Original Assignee
Bioverativ USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ USA Inc filed Critical Bioverativ USA Inc
Publication of AU2016282782A1 publication Critical patent/AU2016282782A1/en
Priority to AU2022215307A priority Critical patent/AU2022215307B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016282782A 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders Abandoned AU2016282782A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022215307A AU2022215307B2 (en) 2015-06-26 2022-08-12 Methods of treating autoimmune and alloimmune disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
US62/185,362 2015-06-26
PCT/US2016/039087 WO2016210172A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022215307A Division AU2022215307B2 (en) 2015-06-26 2022-08-12 Methods of treating autoimmune and alloimmune disorders

Publications (1)

Publication Number Publication Date
AU2016282782A1 true AU2016282782A1 (en) 2018-01-18

Family

ID=57585852

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016282782A Abandoned AU2016282782A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders
AU2022215307A Expired - Fee Related AU2022215307B2 (en) 2015-06-26 2022-08-12 Methods of treating autoimmune and alloimmune disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022215307A Expired - Fee Related AU2022215307B2 (en) 2015-06-26 2022-08-12 Methods of treating autoimmune and alloimmune disorders

Country Status (12)

Country Link
US (3) US20180169240A1 (https=)
EP (1) EP3313417A4 (https=)
JP (1) JP6963509B2 (https=)
KR (1) KR20180020296A (https=)
CN (1) CN108348600A (https=)
AU (2) AU2016282782A1 (https=)
CA (1) CA2990662A1 (https=)
EA (1) EA038567B1 (https=)
HK (1) HK1254030A1 (https=)
IL (1) IL256424B2 (https=)
MX (2) MX2017016835A (https=)
WO (1) WO2016210172A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2016164358A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
AU2017258492B2 (en) 2016-04-29 2023-12-07 Pfizer Inc. Interferon beta antibodies and uses thereof
HUE073475T2 (hu) 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
MX2021013441A (es) 2019-05-15 2021-12-10 Chugai Pharmaceutical Co Ltd Molecula de union a antigenos, composicion farmaceutica y metodo.
TWI856193B (zh) * 2019-10-16 2024-09-21 日商中外製藥股份有限公司 抗體、醫藥組成物及方法
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
WO2004022096A1 (en) * 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
WO2009132058A2 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
CN104870475B (zh) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf

Also Published As

Publication number Publication date
JP6963509B2 (ja) 2021-11-10
IL256424B2 (en) 2024-09-01
AU2022215307A1 (en) 2022-09-08
CA2990662A1 (en) 2016-12-29
US20180169240A1 (en) 2018-06-21
EA038567B1 (ru) 2021-09-15
IL256424A (en) 2018-02-28
MX2017016835A (es) 2018-08-01
EA201890106A1 (ru) 2018-05-31
BR112017027578A2 (pt) 2018-08-28
HK1254030A1 (zh) 2019-07-12
IL256424B1 (en) 2024-05-01
MX2023002021A (es) 2023-03-15
US20220249664A1 (en) 2022-08-11
US20250295768A1 (en) 2025-09-25
EP3313417A1 (en) 2018-05-02
WO2016210172A1 (en) 2016-12-29
EP3313417A4 (en) 2019-06-12
JP2018526330A (ja) 2018-09-13
CN108348600A (zh) 2018-07-31
NZ738570A (en) 2025-05-02
KR20180020296A (ko) 2018-02-27
AU2022215307B2 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
US20250295768A1 (en) Methods of treating autoimmune and alloimmune disorders
AU2013206788B2 (en) Method of providing monoclonal auto-antibodies with desired specificity
CN108779171B (zh) 抗补体因子c1q的fab片段及其应用
US11912769B2 (en) Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28
US10875916B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F
WO2019128708A1 (zh) 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
EP3487531A1 (en) Compositions and methods for treating frontotemporal dementia
US20240076394A1 (en) Modulating the immune response using anti-cd30 antibody-drug conjugates
BR122024005916A2 (pt) Uso de um anticorpo que se liga especificamente ao componente 1s (c1s) do complemento no tratamento de distúrbios autoimunes
HK1259259A1 (zh) 治疗自身免疫病症和同种免疫病症的方法
BR112017027578B1 (pt) Método in vitro de monitoramento da eficácia de um método de tratamento que compreende administrar um anticorpo anti-c1s
US20250304666A1 (en) Anti-complement factor h antibodies
HK40083120A (en) Anti-complement factor c1q fab fragments and uses thereof
HK1262078B (en) Anti-complement factor c1q fab fragments and uses thereof
HK1262078A1 (en) Anti-complement factor c1q fab fragments and uses thereof

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted